| Title | Consultation response to the Medicines and Healthcare Products Regulatory Agency (MHRA) on 'Consultation Letter MLX 311 - Introduction of new offences relating to information submitted in support of an application for the grant, renewal or variation of a marketing authorisation, or in specified circumstances during the currency of an authorisation, information supplied in relation to 'specials', information supplied during the currency of a manufacturer's or wholesale dealer's licence, and additional record-keeping requirements in respect of manufacturers of biological medicinal products for human use' |